Renal Cancer - Results from #740

A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma. September 15, 2023

Contemporary patients have better perioperative outcomes following cytoreductive nephrectomy: a multi-institutional analysis of 1272 consecutive patients. September 14, 2023

The prognostic value of cancer stage-associated genes in clear cell renal cell carcinoma. September 14, 2023

Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy. September 13, 2023

Advanced Non-Clear Cell Renal Cell Carcinoma Treatments and Survival: A Real-World Single-Centre Experience. September 13, 2023

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease? September 12, 2023

Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma. September 12, 2023

Integrating bioinformatic analysis and detailed experiments reveal an EMT-related biomarker for clear cell renal cell carcinoma. September 11, 2023

ABCC2 brush-border expression predicts outcome in papillary renal cell carcinoma: a multi-institutional study of 254 cases. September 11, 2023

The Role of 99mTc-Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta-analysis. September 8, 2023

Clinical application of superselective transarterial embolization of renal tumors in zero ischaemia robotic-assisted laparoscopic partial nephrectomy. September 8, 2023

Real-time Estimation of Nephron Activity with a Linear Measurement System (RENAL-MS) Predicts Postoperative eGFR. September 7, 2023

Kidney function and risk of Renal Cell Carcinoma. September 7, 2023

Perioperative, functional, and oncological outcomes of robotic vs. laparoscopic partial nephrectomy for complex renal tumors (RENAL score ≥7): an evidence-based analysis. September 6, 2023

The Utility of Renal Mass Biopsy in Large Renal Masses. September 6, 2023

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial. September 5, 2023

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. September 5, 2023

Immune-related risk prognostic model for clear cell renal cell carcinoma: Implications for immunotherapy. September 4, 2023

A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors. September 4, 2023

Pre-operative Plasma Fibrinogen Level as a Potential Predictor of Pathological T3 Upstaging in Clinically Localized Renal Cell Carcinoma. September 1, 2023

Page 38 of 456